Literature DB >> 31334537

Multimodality imaging of naturally active melanin nanoparticles targeting somatostatin receptor subtype 2 in human small-cell lung cancer.

Lei Xia1, Xiaoyi Guo, Teli Liu, Xiaoxia Xu, Jinquan Jiang, Feng Wang, Zhen Cheng, Hua Zhu, Zhi Yang.   

Abstract

Somatostatin receptor subtype 2 (SSTR2) is highly expressed in pulmonary neuroendocrine tumors, which account for approximately 25% of all lung cancers including small-cell lung cancer (SCLC). It is possible to establish SCLC-specific imaging agents for multimodal imaging to obtain tumor integrity information. Herein, we constructed novel multifunctional organic melanin nanoparticles (MNPs) as a carrier and surface-loaded somatostatin analog octreotide to produce a human small-cell lung cancer-targeted nanoprobe OCT-PEG-MNPs. MNPs have an excellent photoacoustic imaging (PAI) function and can be directly chelated with the magnetic resonance contrast agent Mn2+, and N-bromo succinimide (NBS) can be used as an oxidant to label the nanoparticles with the long half-life radionuclide 124I by an electrophilic substitution reaction. Therefore, (124I, Mn) OCT-PEG-MNPs can not only be used for PAI but also be used for positron emission tomography (PET) and magnetic resonance imaging (MRI). The NCI-H69 SCLC tumor xenograft model with high SSTR2 expression was constructed to evaluate the multimodal imaging ability of (124I, Mn) OCT-PEG-MNPs. This nanoprobe showed good imaging abilities in PAI, MRI and PET. The PA images showed that the photoacoustic signal in the NCI-H69 tumor site gradually increased with time, and the NCI-H69 xenograft showed a clear increase in the T1-weighted signal intensity after injection of Mn-OCT-PEG-MNPs at 24 h compared to that in the prescan. MicroPET and biodistribution studies showed that the uptake of NCI-H69 tumors (8.03 ± 0.37% ID g-1) was significantly higher than that in the control A549 model (3.35 ± 0.54% ID g-1) after injection of (124I, Mn) OCT-PEG-MNPs at 24 h. The (124I, Mn) OCT-PEG-MNPs were successfully applied to multimodal imaging in a small-cell lung cancer model with high SSTR2 expression. This nanoprobe may be considered for clinical trials since it combines the numerous advantages of organic nanoparticles.

Entities:  

Year:  2019        PMID: 31334537     DOI: 10.1039/c9nr04371c

Source DB:  PubMed          Journal:  Nanoscale        ISSN: 2040-3364            Impact factor:   7.790


  5 in total

Review 1.  MC1R and melanin-based molecular probes for theranostic of melanoma and beyond.

Authors:  Hui Shi; Zhen Cheng
Journal:  Acta Pharmacol Sin       Date:  2022-08-25       Impact factor: 7.169

Review 2.  Transpathology: molecular imaging-based pathology.

Authors:  Mei Tian; Xuexin He; Chentao Jin; Xiao He; Shuang Wu; Rui Zhou; Xiaohui Zhang; Kai Zhang; Weizhong Gu; Jing Wang; Hong Zhang
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-02-13       Impact factor: 9.236

3.  Application Analysis of 124I-PPMN for Enhanced Retention in Tumors of Prostate Cancer Xenograft Mice.

Authors:  Lei Xia; Li Wen; Xiangxi Meng; Nina Zhou; Xiaoyi Guo; Teli Liu; Xiaoxia Xu; Feng Wang; Hua Zhu; Zhi Yang
Journal:  Int J Nanomedicine       Date:  2021-11-16

4.  Preparation and evaluation of LA-PEG-SPION, a targeted MRI contrast agent for liver cancer.

Authors:  Lei Xia; Xiaowei Song; Guanghai Yan; Jishan Quan; Guangyu Jin
Journal:  Open Life Sci       Date:  2022-08-15       Impact factor: 1.311

Review 5.  Bio-Nanocarriers for Lung Cancer Management: Befriending the Barriers.

Authors:  Shruti Rawal; Mayur Patel
Journal:  Nanomicro Lett       Date:  2021-06-12
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.